These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 34327724)

  • 1. Identification of different side effects between PARP inhibitors and their polypharmacological multi-target rationale.
    Sandhu D; Antolin AA; Cox AR; Jones AM
    Br J Clin Pharmacol; 2022 Feb; 88(2):742-752. PubMed ID: 34327724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The kinase polypharmacology landscape of clinical PARP inhibitors.
    Antolin AA; Ameratunga M; Banerji U; Clarke PA; Workman P; Al-Lazikani B
    Sci Rep; 2020 Feb; 10(1):2585. PubMed ID: 32066817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utilization of Poly(ADP-Ribose) Polymerase Inhibitors in Ovarian Cancer: A Retrospective Cohort Study of US Healthcare Claims Data.
    Arend RC; O'Malley DM; Banerjee S; McLaurin K; Davidson R; Long GH
    Adv Ther; 2022 Jan; 39(1):328-345. PubMed ID: 34727316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin II receptor blockers (ARBs) and manufacturing contamination: A retrospective National Register Study into suspected associated adverse drug reactions.
    Salim H; Jones AM
    Br J Clin Pharmacol; 2022 Nov; 88(11):4812-4827. PubMed ID: 35585835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets.
    Knezevic CE; Wright G; Rix LLR; Kim W; Kuenzi BM; Luo Y; Watters JM; Koomen JM; Haura EB; Monteiro AN; Radu C; Lawrence HR; Rix U
    Cell Chem Biol; 2016 Dec; 23(12):1490-1503. PubMed ID: 27866910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poly (ADP-ribose) polymerase (PARP) inhibitor regimens for ovarian cancer in phase III randomized controlled trials: a network meta-analysis.
    Gong H; Nie D; Huang Y; Li Z
    Int J Gynecol Cancer; 2020 Oct; 30(10):1576-1582. PubMed ID: 32817083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suspected adverse drug reactions of the type 2 antidiabetic drug class dipeptidyl-peptidase IV inhibitors (DPP4i): Can polypharmacology help explain?
    Jones L; Jones AM
    Pharmacol Res Perspect; 2022 Dec; 10(6):e01029. PubMed ID: 36468400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real world experience of poly (ADP-ribose) polymerase inhibitor use in a community oncology practice.
    Eakin CM; Ewongwo A; Pendleton L; Monk BJ; Chase DM
    Gynecol Oncol; 2020 Oct; 159(1):112-117. PubMed ID: 32811682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health care services utilization in patients with ovarian cancer receiving PARP inhibitor maintenance treatment in a US community oncology setting.
    Chase DM; Annavarapu S; Tseng WY; Shi J; Szamreta E; Monberg M
    Gynecol Oncol; 2024 Jan; 180():79-85. PubMed ID: 38056115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral Neuropathy Potentially Associated to Poly (ADP-Ribose) Polymerase Inhibitors: An Analysis of the Eudravigilance Database.
    Jesus M; Cabral A; Monteiro C; Duarte AP; Morgado M
    Curr Oncol; 2023 Jul; 30(7):6533-6545. PubMed ID: 37504339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteomic Analysis Reveals Low-Dose PARP Inhibitor-Induced Differential Protein Expression in BRCA1-Mutated High-Grade Serous Ovarian Cancer Cells.
    Perez JM; Twigg CAI; Guan W; Thomas SN
    J Am Soc Mass Spectrom; 2022 Feb; 33(2):242-250. PubMed ID: 34958553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in PARP Inhibitors for the Treatment of Ovarian Cancer: Mechanisms of Action, Pharmacology, Safety, and Efficacy.
    Valabrega G; Scotto G; Tuninetti V; Pani A; Scaglione F
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PARP-inhibitor potpourri: A comparative review of class safety, efficacy, and cost.
    Hennes ER; Dow-Hillgartner EN; Bergsbaken JJ; Piccolo JK
    J Oncol Pharm Pract; 2020 Apr; 26(3):718-729. PubMed ID: 31902284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative safety and tolerability of approved PARP inhibitors in cancer: A systematic review and network meta-analysis.
    Cai Z; Liu C; Chang C; Shen C; Yin Y; Yin X; Jiang Z; Zhao Z; Mu M; Cao D; Zhang L; Zhang B
    Pharmacol Res; 2021 Oct; 172():105808. PubMed ID: 34389457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of efflux transporters by poly ADP-ribose polymerase inhibitors.
    Deng F; Sistonen J; Neuvonen M; Niemi M
    Basic Clin Pharmacol Toxicol; 2023 Oct; 133(4):428-436. PubMed ID: 37539467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of Wnt signaling promotes olaparib resistant ovarian cancer.
    Yamamoto TM; McMellen A; Watson ZL; Aguilera J; Ferguson R; Nurmemmedov E; Thakar T; Moldovan GL; Kim H; Cittelly DM; Joglar AM; Brennecke EP; Wilson H; Behbakht K; Sikora MJ; Bitler BG
    Mol Carcinog; 2019 Oct; 58(10):1770-1782. PubMed ID: 31219654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The emerging role of PARP inhibitors in prostate cancer.
    Stellato M; Guadalupi V; Sepe P; Mennitto A; Claps M; Zattarin E; Verzoni E; Valdagni R; De Braud FG; Santini D; Tonini G; Procopio G
    Expert Rev Anticancer Ther; 2020 Aug; 20(8):715-726. PubMed ID: 32758032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials.
    Ruscito I; Bellati F; Ray-Coquard I; Mirza MR; du Bois A; Gasparri ML; Costanzi F; De Marco MP; Nuti M; Caserta D; Pignata S; Dorigo O; Sehouli J; Braicu EI
    Cancer Treat Rev; 2020 Jul; 87():102040. PubMed ID: 32485510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors.
    Lee EK; Matulonis UA
    Expert Opin Emerg Drugs; 2020 Jun; 25(2):165-188. PubMed ID: 32569489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.